When was jazz pharmaceuticals founded

Find RelSci relationships, employment history, board memberships, donations, awards, and more. Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections. Harness the power of your relationships with RelSci, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward. Date Founded. Type of Company.

Employees Worldwide. Company Description. Contact Data. Trying to get in touch with decision makers at Jazz Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits! In The News. Jazz's Xywav scores the first FDA nod in idiopathic hypersomnia, and big sales could follow.

Jazz clinches Rylaze green light in 2 blood cancers, including the most common cancer among children. Bruce C. Daniel N. Swisher, Jr. Gene C. Neena M.

Heidi Manna. Robert Iannone. Kim Sablich. Valerie L. Iain Robert McGill. Zaffaroni passed away in March Sign in or Sign-up. Beyond The Printed Page June 1, Newsletter Signup. I agree to the Terms. I agree to the Privacy Statement. If desirable means you have good products, good employees, good prospects, good pipeline, of course you want to be on that list. Then your shareholders are not dependent on selling as the only way to realise value.

But the company has managed to stay clear of the debate. In part, that was due to its size but also, Cozadd argues, Jazz has gone much further than simply using Ireland as a convenient tax base.

We also have the manufacturing plant in Athlone. This has become an important hub for us for what we do both in Europe as well as the US.

It has fit into our overall growth in a very strategic way. Meaning that there are great commercial products that we can bring to the market today, but also an area where we can continue to develop new products. Working in the specialty pharma space, pricing and cost are recurring issues.

Developing a drug for a smaller patient population costs just as much as for a larger group — and getting that money back means the price of treatment is high.

Is it clear the products we have deliver real value to patients, that the problem we are helping to address is a serious problem, and that our drug really does address it — not that it makes a some very small difference, but that it really does change things for the better? His experience is that, in general, most healthcare systems want to pay for those kind of drugs.

But he argues also that pricing and reimbursement schemes must reward innovation. For now, though, pricing is not an issue. The success of its therapies mean Jazz has recently been able to increase the price of Xyrem even as it grows its reach.

Interests: Music, not surprisingly, and travel. Something you might expect: as founder of a company named Jazz, Cozadd has a passion for music of all sorts, especially musical theatre. Something that might surprise you: Before Cozadd entered the world of biopharmaceutical development and production, he worked on Wall Street. See a sample. Please update your payment details to keep enjoying your Irish Times subscription.

Jazz Pharma hits all the right notes Jazz by name and jazzy by metaphor, the Irish firm is now a muscular player in the pharmaceutical world. Dominic Coyle.